Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab interval lengthening in IBD remission
NL-OMON20310Recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of adalimumab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by Erasmus MC. Primary endpoint: Patients in remission at 24 weeks. Started Apr 2014; status: recruiting.
02
Drugs
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON20310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20310.